Park Kyung-Rock, Kim Kyu-Beom, Baek Yeon-Hee, Sung Hi Gin, Park Jung-Tae, Lee Eui-Kyung, Shin Ju-Young
School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeong gi-do, South Korea.
Int J Clin Pharm. 2018 Dec;40(6):1568-1576. doi: 10.1007/s11096-018-0739-0. Epub 2018 Oct 26.
Background Benzodiazepine use can potentially cause confusion and delays in mental processes. These well-known side effects appear to be linked to an increased risk of being diagnosed with dementia. Objective To evaluate the possibility of an association between benzodiazepine and dementia. Setting Korean healthcare database from 2002 to 2013. Methods Sequence symmetry analysis was conducted to investigate whether benzodiazepine use increases the risk of dementia or not. We defined exposure as new benzodiazepine users and outcome as new diagnosis of dementia (ICD-10: F00-03, G30, and G318). Benzodiazepines were categorized into two groups (long-acting and short-acting) based on the duration of action. Antidepressants, opioid analgesic, and statin were used as active comparators to rule out any possible non-causal interpretations of our results. The time-trend adjusted sequence ratio (ASR) with 95% confidence intervals (CI) was measured to identify possible associations. Main outcome measure Adjusted sequence ratio. Results Benzodiazepine users were shown to be associated with dementia [benzodiazepine: 4212 pairs, ASR = 2.27 (95% CI 2.11-2.44)]. In addition, long-acting benzodiazepines had a higher ASR than that of short-acting benzodiazepines [long-acting: 3972 pairs, ASR = 2.22 (95% CI 2.06-2.39] and [short-acting: 5213 pairs, ASR = 1.88 (95% CI 1.77-2.00)]. However, our SSA found no duration-response relationship. Conclusion Our signal detection suggests that there is a possible association between benzodiazepines and dementia. Additionally, it proposes that persons receiving long-acting benzodiazepines are at a higher risk of developing dementia than those receiving short-acting benzodiazepines. Further studies are recommended to confirm whether this epidemiological association is a causal effect or not.
使用苯二氮䓬类药物可能会导致思维混乱和精神过程延迟。这些众所周知的副作用似乎与被诊断为痴呆症的风险增加有关。目的:评估苯二氮䓬类药物与痴呆症之间存在关联的可能性。研究背景:2002年至2013年韩国医疗保健数据库。方法:进行序列对称性分析,以调查使用苯二氮䓬类药物是否会增加患痴呆症的风险。我们将暴露定义为新使用苯二氮䓬类药物的人群,将结局定义为新诊断的痴呆症(国际疾病分类第十版:F00 - 03、G30和G318)。根据作用持续时间,苯二氮䓬类药物被分为两组(长效和短效)。使用抗抑郁药、阿片类镇痛药和他汀类药物作为活性对照,以排除对我们结果的任何可能的非因果性解释。测量具有95%置信区间(CI)的时间趋势调整序列比(ASR),以确定可能的关联。主要结局指标:调整后的序列比。结果:使用苯二氮䓬类药物的人群显示与痴呆症有关联[苯二氮䓬类药物:4212对,ASR = 2.27(95% CI 2.11 - 2.44)]。此外,长效苯二氮䓬类药物的ASR高于短效苯二氮䓬类药物[长效:3972对,ASR = 2.22(95% CI 2.06 - 2.39)]和[短效:5213对,ASR = 1.88(95% CI 1.77 - 2.00)]。然而,我们的序列对称性分析未发现剂量 - 反应关系。结论:我们的信号检测表明苯二氮䓬类药物与痴呆症之间可能存在关联。此外,研究表明接受长效苯二氮䓬类药物的人患痴呆症的风险高于接受短效苯二氮䓬类药物的人。建议进一步研究以确认这种流行病学关联是否为因果效应。